Estrella Immunopharma adds fourth site to lymphoma trial Aug 11, 2026 08:01AM
Estrella adds Oregon Health & Science University to lymphoma trial Aug 3, 2026 08:03AM
Estrella Immunopharma adds Baylor site to lymphoma trial Jul 29, 2026 08:01AM
Estrella Immunopharma doses first patient in EB103 expansion trial Jul 24, 2026 08:00AM
Estrella Immunopharma reports positive phase 1 data for cancer therapy Feb 9, 2026 07:01AM


Jan 16, 2026 05:10PM Estrella Immunopharma (ESLA) files for 9.24M share offering by selling stockholders
Dec 22, 2025 10:58AM Estrella Immunopharma (ESLA) files for 2.54M share offering by selling stockholders
Dec 4, 2025 08:03AM Estrella advances cancer therapy trial to phase II after safety review
Nov 3, 2025 10:02AM Estrella Immunopharma reports complete response in EB103 lymphoma trial
Jun 5, 2025 08:03AM Estrella Immunopharma (ESLA) Announces Activation of Additional Site for Phase I/II STARLIGHT-1 Trial
Jun 3, 2025 08:00AM Estrella Immunopharma (ESLA) Announces 2.33M Share Offering at $1.50/sh
Feb 21, 2025 08:32AM Estrella Immunopharma (ESLA) Completes First Dose Cohort in STARLIGHT-1 Trial, Receives Approval to Initiate Higher Dose Cohort
Sep 27, 2024 12:00PM Estrella Immunopharma (ESLA) Achieves Complete Response in First Patient Treated with CD19- Redirected ARTEMIS T-cells
Aug 14, 2024 12:00PM Estrella Immunopharma (ESLA) Appoints Hong Zhang as Board Chair